• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Study produces ‘promising results’ for Carthera’s SonoCloud tech for mild Alzheimer’s symptoms

Study produces ‘promising results’ for Carthera’s SonoCloud tech for mild Alzheimer’s symptoms

March 31, 2022 By Sean Whooley

Carthera SonoCloud Alzheimer's
[Image from Carthera’s website]
Carthera announced positive results from a trial evaluating the safety and efficacy of the use of its SonoCloud technology.

Results from the investigator-sponsored trial of SonoCloud in patients with mild Alzheimer’s Disease (AD) were published this week in the Alzheimer’s Research & Therapy Journal.

Paris-based Carthera designed SonoCloud, an implantable 1 MHz ultrasound device, to be activated on-demand using a transdermal needle connected to an external interface. The company said in a news release that the platform, which delivers low-intensity pulsed ultrasound (LIPU) to temporarily disrupt the blood-brain barrier (BBB), reduced β-amyloid and tau pathologies and improved cognitive performance in Alzheimer’s preclinical models.

Professor Alexandre Carpentier and Dr. Stéphane Epelbaum conducted a translational study at Hôpital de la Pitié-Salpêtrière (AP-HP Sorbonne, Paris, France) that follows previous trials displaying Sonocloud’s potential. The aim of the study was to demonstrate the safety of the technology in patients with mild AD, as well as to explore whether ultrasound alone could reduce their amyloid load.

In the trial, patients with mild AD had a single-emitter version of the SonoCloud implanted under local anesthesia to target the left supramarginal gyrus. Seven ultrasound sessions — lasting approximately 10 minutes each — over three and a half months were performed twice per month on nine patients to temporarily disrupt the BBB.

PET imaging was performed at inclusion and at four and eight months after initial sonications to monitor brain metabolism and amyloid levels. The trial showed that SonoCloud can disrupt the BBB in Alzheimer’s patients and it further confirmed the safety previously demonstrated in patients with brain tumors.

Additionally, researchers observed a slight decrease in amyloid load in the majority of patients despite the short treatment and observation window, which Carthera said demonstrates the therapeutic potential of the modality previously observed in preclinical models.

“We’re currently planning a clinical trial that will lead to marketing authorization of the SonoCloud for the treatment of glioblastoma while also continuing to explore this technology in a greater number of brain indications in combination with various therapeutic agents,” Carthera CEO Frédéric Sottilini said in the release. “The outcomes of this study reinforce our conviction that the SonoCloud has the potential to unlock the efficacy of therapies for brain diseases that were previously untreatable.”

Filed Under: Bioelectronic Medicine, Clinical Trials, Featured, Imaging, Implants, Neurological, Neuromodulation/Neurostimulation, News Well, Oncology, Ultrasound Tagged With: CarThera

More recent news

  • Imperative Care has positive stroke treatment study results
  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • Intuitive demonstrates remote telesurgery capabilities with da Vinci 5
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • CVRx announces Medicare win for Barostim therapy

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy